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Introduction
By reducing tumor vascularity, viability, and peri-
tumor edema, neoadjuvant chemotherapy may facili-
tate limb-sparing resections and reduce the number of
amputations. The combination of multiagent chemo-
therapy and surgery has dramatically improved the
prognosis for patients with primary bone and soft tis-
sue sarcoma. Neoadjuvant chemotherapy also allows
histologic assessment of the tumor response. Further-
more, neoadjuvant chemotherapy permits the design
of reconstruction method after surgical resection.
Short-term assessment of tumor response gener-
ally involves the sequential measurement of tumor
size either clinically or by imaging. These assessments
may not always reflect the quantity of residual viable
tumor cells because of edema, hemorrhage, and
necrosis.1,2 Also, because osseous lesions, such as
osteosarcoma and Ewing’s sarcoma, frequently do
not change in size in response to chemotherapy,
radiographic evaluation of response by computed
tomography (CT) or magnetic resonance imaging
(MRI) does not discriminate between responding and
nonresponding tumors.3 F-18-fluorodeoxy-D-glucose
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Prognostic significance of PET in primary osteosarcoma
positron emission tomography (F-18-FDG PET) is
an alternative imaging modality. PET imaging differs
considerably from conventional imaging modalities
such as MRI, CT, and ultrasonography because it
quantifies the functional activity of tissue by using a
labeled glucose analog, FDG, but not its morpho-
logic abnormality.4 Tumor tissues generally show
enhanced glycolysis,5 and elevated uptake of FDG
determined by PET has been reported in malignant
mesenchymal tumors in a limited number of stud-
ies.6,7 FDG-PET has been proposed as a diagnostic
tool for discriminating benign and malignant soft tis-
sue and osseous lesions,8–11 for the grading of sarco-
mas,10,12 and for the detection of local recurrence.13
The aim of the current study was to evaluate the
reliability of FDG-PET in the assessment of neoadju-
vant chemotherapy response in osteosarcoma patients
by correlation with histology.
Methods
Patients
This prospective study was conducted at the Depart-
ment of Orthopedics and Traumatology, Department
of Nuclear Medicine, and Department of Pathology,
Taipei Veterans General Hospital. Patients attending
our outpatient department who met all the following
criteria were included:
1. Biopsy-proven primary osteosarcoma;
2. Newly diagnosed, had not been treated at other
hospitals;
3. Solitary lesion; no other bone or lung metastasis;
4. Allowed and planned to be treated with neoadju-
vant chemotherapy before the definite tumor
resection surgery;
5. No pathologic fracture.
The study was approved by the hospital review board.
Procedure
All patients underwent PET imaging twice with FDG:
first, in the week before initiation of neoadjuvant
chemotherapy; second, in the week after the comple-
tion of neoadjuvant chemotherapy. FDG uptake was
quantitated using average standardized uptake value
(SUV). All data recording FDG uptake were obtained
twice from the 2 PET images. Positive prognostic sig-
nificance was defined as more than 90% tumor necro-
sis response following neoadjuvant chemotherapy. The
neoadjuvant chemotherapy regimens employed con-
tained high-dose methotrexate, doxorubicin, cisplatin,
and ifosfamide, and they generally followed the pro-
tocols employed by the Pediatric Oncology Group.14
All data were subjected to Pearson’s correlation coef-
ficient model analysis. SUV, a quantitative index of




The tumor necrosis rate was quantified using tumor-
to-nontumor ratios from PET-2 imaging. Thus, a
region of interest was drawn to follow the contours of
the elevated FDG activity in the axial slice with maxi-
mum tumor activity. An identical region of interest
representing background activity was placed around
comparable unaffected tissue on the contralateral side.
The PET-2 scans were sliced into pixels and compared
with the background activity to quantify the tumor-
to-nontumor ratios. The percentage of nontumor area
was defined as the tumor necrosis rate.
Comparison between tumor necrosis rates, PET and
histology was made with intraclass correlation coeffi-
cient model.
PET scanning
Patients fasted for more than 2 hours before the pro-
cedure. They then signed informed consent forms for
the procedure and received 7–10 mCi of FDG i.v. over
2 minutes. After a 45-minute equilibration period dur-
ing which the patient was at rest, attenuation-corrected
emission images over the tumor were acquired on a
Siemens EXACT HR + PET scanner. Typically, the
tumor extent was captured in 2 adjoining 15 cm fields
of view. Reconstructed attenuation-corrected images
were viewed in the transaxial planes and hand drawn
regions of interest were placed over the tumor for cal-
culation of the SUV. Regions of interest were drawn
to follow the contours of the elevated FDG activity as
compared to normal tissue, contralateral to the tumor
site (Figures 1 and 2). The SUV was generated by the
tomographic software as the ratio mentioned above.
Histologic response to neoadjuvant
chemotherapy
Response to chemotherapy was assessed in the
postchemotherapeutic surgical specimens according
to the well-established and highly reproducible classi-
fication of Salzer-Kuntschik (grades I to VI).15,16 The
percentage of vital areas in relation to the entire
tumor area was determined by an experienced pathol-
ogist who examined the slices of the resected speci-
mens independently of clinical or imaging findings.
The area of tumor necrosis was determined by exam-
ining the largest histologic section. A good response
to chemotherapy was defined as less than 10% residual
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vital tumor area; 10% vital tumor area or more indi-
cated a poor response.
Statistical analysis
Comparison between tumor necrosis rates calculated
by different modalities, PET and histology, was made
with the intraclass correlation coefficient model. The
intraclass correlation coefficient, r, ranges from 0 to 1,
with r= 0 indicating no correlation at all and r= 1
indicating perfect correlation.
Results
Between January and December 2003, 10 patients
with primary osteosarcomas were examined using FDG
PET before neoadjuvant chemotherapy and surgery.
The mean age at the time of first intervention was 
19 years (range, 4–47 years). All patients underwent
PET imaging twice with FDG: before initiation and
after the completion of neoadjuvant chemotherapy.
Eight patients were male, and 2 were female. Four
cases involved the distal femurs, 3 proximal tibias, 1
proximal humerus, 1 proximal fibula, and 1 involved
the proximal femur. Regarding histology type, 7 were
osteoblastic, 1 was fibroblastic, 1 was chondroblastic,
and 1 was of mixed type. The tumor necrosis rate deter-
mined by FDG PET was compared with that deter-
mined histologically. The mean SUV value before
neoadjuvant chemotherapy was 8.2 (1.4–13.6), and
the mean SUV value following neoadjuvant chemo-
therapy was 4.4 (1.7–9.6). The average tumor necro-
sis rates determined by PET and histology were 
22% (11–39%) and 54.5% (17.5–100%), respectively
(Table 1). According to the intraclass correlation
coefficient models, the r value was 0 (Table 2). The
relationship of tumor necrosis rate between PET and
histology seemed to be statistically insignificant.
Discussion
The histologic response to neoadjuvant chemotherapy
is an important prognostic indicator of disease-free sur-
vival following treatment of primary musculoskeletal
malignant neoplasms, in particular osteogenic sarcoma
and Ewing’s sarcoma.1,2,17,18 Furthermore, we also
used the histologic response following neoadjuvant
chemotherapy to guide the selection of alternative
Figure 2. F-18-FDG PET study after neoadjuvant chemotherapy in
the same patient (Case 4).
Table 1. Details of the 10 patients in the current study
Patient
Age
Sex Tumor site SUV1 SUV2
Necrosis rate 
(yr) PET (%) Histology (%)
1 47 F Proximal femur 7.3 5.0 26 38
2 15 M Proximal tibia 11.7 9.6 30 50
3 18 M Proximal tibia 9.3 3.2 20 100
4 17 M Distal femur 12.6 5.4 20 33
5 4 M Proximal tibia 9.4 6.7 24 15
6 24 M Proximal fibular 2.7 2.5 16 75
7 19 M Distal femur 13.6 2.2 17 100
8 5 M Proximal humerus 1.4 1.7 11 66
9 26 M Distal femur 9.0 4.8 17 17.5
10 15 F Distal femur 5.4 2.5 39 50
SUV = standardized uptake value; PET = positron emission tomography.
Figure 1. The F18-FDG PET study before neoadjuvant chemo-
therapy was performed on a 17-year-old boy (Case 4) with osteo-
sarcoma on his right distal femur.
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postoperative chemotherapy in an attempt to improve
event-free survival rate.17,19,20 Less than 90% tumor
necrosis response following presurgical treatment
denotes a poor response and is associated with a less
favorable outcome.1 Given the surgical and prognostic
implication of adequate histologic response, a reliable
noninvasive surrogate marker of histologic response
would be valuable in determining the efficacy of
neoadjuvant chemotherapy before surgical resection.
Recently, PET was shown to be valuable in assessing
the therapeutic response in various malignant condi-
tions.21,22 Additionally, the ability of PET to detect and
grade musculoskeletal sarcomas and their recurrence
has been shown in several studies.4,6,7 Nieweg et al7
described the absence of FDG uptake within a treated
soft tissue sarcoma, which correlated histologically with
tumor necrosis. Shulkin et al23 reported decreasing
FDG accumulation in a responding Ewing’s sarcoma
during chemotherapy and radiation. The potential role
of FDG PET in monitoring response to therapy has
been shown by Jones et al24 in a small, heterogeneous
group of patients with soft tissue and bone tumors.
Another study from the Netherlands showed substantial
decreases in the glucose metabolism of soft tissue sar-
comas, with a pathologically complete response after
a hyperthermic isolated limb perfusion.25
It is anticipated that tumor activity will be decreased
after neoadjuvant chemotherapy. Our results demon-
strated the fact that, of our 10 patients, in only 1
(patient 8) was the SUV2 larger than SUV1. We attrib-
ute this exception to excess inflammatory process that
could also increase glucose uptake. This may occur in
some patients after chemotherapy. With regard to the
tumor necrosis rate, the necrosis rates calculated by
PET were smaller than those by histology in 9 of 10
patients. We ascribe this to PET tending to have a
false-positive evaluation, which is supported by other
studies.26,27
Our results showed that the correlation between
PET and histology in determining the tumor necrosis
rate was statistically insignificant. We attribute this to 2
reasons: the first being the relatively small case number
and the other is that the regions of interest might 
be positioned in a different plane. Conventionally, our
pathologists examined the largest histologic section
for calculating the tumor necrosis rate. However, the
selected plane might be transaxial, coronal, or sagittal
and might, frequently, not be the same plane as that
used by PET. These 2 factors also contribute to the
major drawbacks of the current study.
In the present study, we used the intraclass corre-
lation coefficient model to verify the relationship of
the necrosis rates determined by 2 different methods,
histology and PDG PET. However, the r value was 0.
The relationship of tumor necrosis rate between FDG
PET and histology seemed to be statistically insignifi-
cant. Because the case numbers of this preliminary
study were relatively small, they may be insufficient to
make such a conclusion. We look forward to larger
series to evaluate the clinical significance of FDG PET
in osteosarcoma patients.
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